[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200100089A1 - Предотвращение рецидива мигрени - Google Patents

Предотвращение рецидива мигрени

Info

Publication number
EA200100089A1
EA200100089A1 EA200100089A EA200100089A EA200100089A1 EA 200100089 A1 EA200100089 A1 EA 200100089A1 EA 200100089 A EA200100089 A EA 200100089A EA 200100089 A EA200100089 A EA 200100089A EA 200100089 A1 EA200100089 A1 EA 200100089A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
migrain
retain
Prior art date
Application number
EA200100089A
Other languages
English (en)
Other versions
EA004036B1 (ru
Inventor
Невилль Колин Джэксон
Стефен Аден
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200100089A1 publication Critical patent/EA200100089A1/ru
Publication of EA004036B1 publication Critical patent/EA004036B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к применению элетриптана, или его фармацевтически приемлемой соли, или композиции для производства лекарственного препарата для предотвращения рецидива мигрени и к применению агониста рецептора 5HT, или его фармацевтически приемлемой соли, или композиции для производства фармацевтической композиции двойного, пролонгированного, отсроченного, регулируемого или пульсирующего высвобождения для предотвращения рецидива мигрени.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100089A 1998-07-30 1999-06-14 Предотвращение рецидива мигрени EA004036B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816556.6A GB9816556D0 (en) 1998-07-30 1998-07-30 Therapy
PCT/IB1999/001105 WO2000006161A1 (en) 1998-07-30 1999-06-14 Prevention of migraine recurrence

Publications (2)

Publication Number Publication Date
EA200100089A1 true EA200100089A1 (ru) 2001-08-27
EA004036B1 EA004036B1 (ru) 2003-12-25

Family

ID=10836395

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200100089A EA004036B1 (ru) 1998-07-30 1999-06-14 Предотвращение рецидива мигрени
EA200201149A EA200201149A1 (ru) 1998-07-30 1999-06-14 Фармацевтические композиции и способы для предотвращения рецидива мигрени

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200201149A EA200201149A1 (ru) 1998-07-30 1999-06-14 Фармацевтические композиции и способы для предотвращения рецидива мигрени

Country Status (35)

Country Link
EP (3) EP1435237A1 (ru)
JP (1) JP3824863B2 (ru)
KR (2) KR100441732B1 (ru)
CN (2) CN1522697A (ru)
AP (1) AP1402A (ru)
AT (1) ATE261304T1 (ru)
AU (1) AU3952199A (ru)
BG (1) BG65309B1 (ru)
BR (1) BR9912588A (ru)
CA (1) CA2338901C (ru)
CZ (1) CZ2001357A3 (ru)
DE (1) DE69915486T2 (ru)
DK (1) DK1100499T3 (ru)
EA (2) EA004036B1 (ru)
EE (1) EE04703B1 (ru)
ES (1) ES2214027T3 (ru)
GB (1) GB9816556D0 (ru)
GE (2) GEP20063719B (ru)
HR (1) HRP20010079A2 (ru)
HU (1) HUP0103424A3 (ru)
ID (1) ID26996A (ru)
IL (1) IL140169A0 (ru)
IS (1) IS2253B (ru)
NO (1) NO20010489L (ru)
NZ (2) NZ508736A (ru)
OA (1) OA11576A (ru)
PL (1) PL194611B1 (ru)
PT (1) PT1100499E (ru)
SG (1) SG125910A1 (ru)
SK (1) SK1182001A3 (ru)
TR (1) TR200100314T2 (ru)
TW (2) TW537893B (ru)
UA (1) UA76399C2 (ru)
WO (1) WO2000006161A1 (ru)
YU (2) YU6401A (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2670272C2 (ru) * 2012-04-18 2018-10-22 Контера Фарма Апс Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
JP4616009B2 (ja) * 2002-12-26 2011-01-19 ポーゼン インコーポレイテッド NSAIDsおよびトリプタンを含有する多層剤型
BRPI0409127A (pt) 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
EP2306998A4 (en) 2008-06-20 2011-06-15 Alphapharm Pty Ltd PHARMACEUTICAL FORMULATION
WO2011048496A1 (en) * 2009-10-23 2011-04-28 Fortuderm, Ltd. Triptans for the treatment of psoriasis
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
CN104523709A (zh) * 2014-12-22 2015-04-22 青岛正大海尔制药有限公司 一种含有琥珀酸夫罗曲坦的复方缓释制剂
KR102443161B1 (ko) 2016-07-11 2022-09-14 콘테라 파르마 에이/에스 아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9190141U1 (de) * 1990-10-15 1993-07-15 Pfizer Inc., New York, N.Y. Indolderivate
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
BR9710289A (pt) * 1996-07-11 1999-08-17 Farmarc Nederland Bv Composi-Æo farmac-utica contendo sal cido de adi-Æo de medicamento b sico
JP3350061B2 (ja) * 1997-07-03 2002-11-25 ファイザー・インク エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2670272C2 (ru) * 2012-04-18 2018-10-22 Контера Фарма Апс Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений

Also Published As

Publication number Publication date
SG125910A1 (en) 2006-10-30
AP1402A (en) 2005-04-29
TR200100314T2 (tr) 2001-06-21
DE69915486T2 (de) 2005-03-03
EE04703B1 (et) 2006-10-16
HUP0103424A2 (hu) 2002-02-28
EP1435237A1 (en) 2004-07-07
TW200300674A (en) 2003-06-16
CA2338901C (en) 2008-02-19
AU3952199A (en) 2000-02-21
TW537893B (en) 2003-06-21
EP1466601A3 (en) 2005-04-13
AP2001002056A0 (en) 2001-03-31
ATE261304T1 (de) 2004-03-15
WO2000006161A1 (en) 2000-02-10
EP1100499B1 (en) 2004-03-10
SK1182001A3 (en) 2001-10-08
GEP20063719B (en) 2006-01-10
BR9912588A (pt) 2001-05-02
DK1100499T3 (da) 2004-06-14
BG105277A (en) 2001-11-30
YU6401A (sh) 2004-03-12
IL140169A0 (en) 2002-02-10
NO20010489D0 (no) 2001-01-29
IS2253B (is) 2007-06-15
JP3824863B2 (ja) 2006-09-20
CA2338901A1 (en) 2000-02-10
CN1155379C (zh) 2004-06-30
EP1466601A2 (en) 2004-10-13
JP2002521446A (ja) 2002-07-16
CZ2001357A3 (cs) 2001-10-17
NZ527625A (en) 2005-01-28
PL345803A1 (en) 2002-01-02
TWI248362B (en) 2006-02-01
EE200100061A (et) 2002-06-17
NZ508736A (en) 2003-09-26
BG65309B1 (bg) 2008-01-31
HUP0103424A3 (en) 2003-05-28
PL194611B1 (pl) 2007-06-29
KR100441732B1 (ko) 2004-07-27
KR20030078876A (ko) 2003-10-08
YU20303A (sh) 2006-08-17
PT1100499E (pt) 2004-06-30
EA200201149A1 (ru) 2003-02-27
CN1522697A (zh) 2004-08-25
EA004036B1 (ru) 2003-12-25
GB9816556D0 (en) 1998-09-30
HK1038198A1 (en) 2002-03-08
ES2214027T3 (es) 2004-09-01
DE69915486D1 (de) 2004-04-15
KR20010079582A (ko) 2001-08-22
IS5771A (is) 2000-12-15
UA76399C2 (en) 2006-08-15
GEP20043157B (en) 2004-01-26
OA11576A (en) 2004-07-01
NO20010489L (no) 2001-03-26
ID26996A (id) 2001-02-22
CN1309560A (zh) 2001-08-22
HRP20010079A2 (en) 2002-02-28
EP1100499A1 (en) 2001-05-23

Similar Documents

Publication Publication Date Title
NO20100041L (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
EA200400589A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
EA200100089A1 (ru) Предотвращение рецидива мигрени
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
AU3955199A (en) Remedies for itching containing PGD2 antagonists
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
SE9302218D0 (sv) New use
BG106151A (en) Pharmaceutical complex
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
MA27262A1 (fr) Microcapsules pour la liberation retardee et controlee du perindopril
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
BRPI0409127A (pt) combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU